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Background 
PCOS was first described by Stein and Leventhal in 1935 [10], but 
until 2003 no agreement existed as to the diagnostic criteria [11]. 
In 2003, the Rotterdam criteria were proposed [12]. The Rotter-
dam criteria are the following:  
1. Irregular/no ovulations 
2. Clinical/paraclinical hyperandrogenaemia 
3. Polycystic ovaries 
Two out of three criteria need to be fulfilled and other causes of 
the patient’s symptoms should be excluded.  
Most patients with PCOS are insulin resistant and about 50% of 
patients fulfil the criteria for the metabolic syndrome [13;14]. The 
exact mechanism for insulin resistance is undetermined, but the 
patients may have defects in the insulin-stimulated glucose me-
tabolism [13;15]. Impaired beta-cell function is also present in 
PCOS and the risk for type 2 diabetes (T2D) is five- to eight fold in-
creased in patients with PCOS compared to weight and age 
matched female controls [1]. Insulin stimulates p450c17 activity 
in ovaries and adrenals leading to increased androgen production 
[16]. The pathogenesis of PCOS involves hyperandrogenemia, 
central obesity, and insulin resistance/ hyperinsulinemia (Figure 
1) [16]. High testosterone levels promote abdominal obesity, 
which may induce insulin resistance [17]. Insulin resistance in-
duces hyperinsulinemia and subsequently stimulates the ovarian 
and adrenal hormonal production, inhibits sex hormone binding 
globulin (SHBG) production, and thereby testosterone activity in-
creases.  
Insulin resistance and central obesity in PCOS is associated with 
increased inflammatory activity and increased secretion of adi-
pokines, interleukins, and chemokines [16], which may increase 
the long tem risk of diabetes and cardiovascular disease [18]. 
Which metabolic risk markers that associate best with the long 
term metabolic risk in PCOS remain to be established.  
 
Figure 1: Pathogenic mechanisms of PCOS 
 
Four different PCOS phenotypes may be defined when the Rotter-
dam criteria are applied [19]. One of these phenotypes includes 
patients with polycystic ovaries, irregular menses, and no signs of 
hyperandrogenemia [12]. The inclusion of patients without hyper-
androgenemia in the definition of PCOS is currently debated. The 
metabolic disturbances of PCOS are more pronounced in hyper-
androgen patients compared to patients with no hyperandroge-
naemia [20]. The PCOS phenotype may therefore be a predictor 
of metabolic and cardiovascular risk. The task force of the Andro-
gen Excess and PCOS Society suggested that the diagnosis of 
PCOS should not be established in patients without signs of hy-
perandrogenaemia [20]. How PCOS is best diagnosed remains to 
be determined. The estimated prevalence of PCOS varies from 5-
20% depending of the applied criteria [21]. PCOS is therefore the 
most frequent endocrinopathy in reproductive-aged women 
[21;22]. In the present thesis, the used definition of PCOS has 
been described in each paper.  
 
Hirsutism is defined as an increased growth of terminal hair in a 
male pattern in women. The prevalence of hirsutism is more than 
25% in reproductive aged women [22]. Hirsutism is caused by in-
creased androgenicity in the pilo-sebacceus gland resulting in in-
creased growth of terminal hair [23;24]. Hirsute patients have in-
creased dermal activity of the enzyme 5α-reductase, which is 
responsible for the conversion of testosterone to the more potent 
androgen dihydrotestosterone [25]. Individual variations in der-
mal 5α-reductase activity may explain that hirsute patient often 
have often near-normal testosterone levels and that circulating 
testosterone levels are not associated with clinical hirsute mani-
festations [25].  
95% of hirsute patients are diagnosed with PCOS or idiopathic hir-
sutism. Idiopathic hirsutism is defined as hirsutism with regular 
ovulation and normal testosterone levels [25]. Depending on the 
methods applied, the prevalence of idiopathic hirsutism varies 
from 5-25% of hirsute patients [23;26]. In daily practice, PCOS and 
idiopathic hirsutism is difficult do distinguish and the two terms 
probably represent a continuum [16]. Several studies described 
metabolic and endocrine disturbances in idiopathic hirsutism sim-
ilar to what is observed in PCOS [27;28]. 
 
Insulin resistance
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Testosterone
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Inflammation
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Treatment modalities in PCOS aim at decreasing hyperandrogen-
ism and improving insulin sensitivity, but the long term treatment 
strategy in patients with PCOS is still debated [29;30]. The most 
commonly used treatment modalities in PCOS patients without 
current pregnancy wish are oral contraceptives (OCP) and insulin 
sensitizers. OCP regulates menstrual cycles and SHBG levels are 
increased, leading to decreased levels of free testosterone and 
decreased hirsutism scores [31]. However, in short term studies 
OCP was associated with adverse effects on glucose metabolism 
[32]. OCP cannot be used in very obese patients and patients with 
other contraindications for OCP including previous or family his-
tory of thrombosis or breast cancer, coagulatory defects or heav-
ily smokers.  
Insulin sensitizing treatment most commonly includes lifestyle in-
tervention and metformin treatment.  The aim of insulin sensitiz-
ing treatment is to improve insulin resistance and, thereby, insu-
lin stimulation of adrenal and ovarian androgen production 
decreases [33]. Weight loss improves clinical and biochemical 
manifestations of PCOS, but the patients’ adherence to life style 
intervention is often limited [34]. Treatment with metformin in-
creases insulin sensitivity and improves ovulatory function in 
PCOS [31], whereas androgen levels and hirsutism scores are only 
mildly improved or unchanged [31;35]. Metformin treatment is 
associated with gastrointestinal side effects including nausea, 
which often wear off during long-term treatment and could affect 
endocrine and metabolic outcomes. 
The thiazolidinediones rosiglitazone and pioglitazone stimulate 
the peroxisome proliferator-activated (PPAR)-γ receptors in the 
cell nucleus and activate the transcription of genes that affect glu-
cose and lipid metabolism mediating decreased peripheral adipo-
cyte lipolysis, decreased free fatty acid (FFA) levels, and de-
creased visceral fat mass [36;37]. The treatment with PPAR-γ 
agonists may be associated with decreased bone mineral density 
and is contraindicated in patients with pregnancy wish [33]. In the 
present thesis, studies on PPAR-γ-agonist treatment were used to 
investigate pathogenic mechanisms of insulin resistance in PCOS. 
In the daily clinic, PPAR-γ-agonist treatment is not indicated in pa-
tients with PCOS.  
Methods 
Evaluation of hormone concentrations  
In the present theses, blood samples were collected in the morn-
ing during follicular phase whenever possible. Medical treatment 
was paused three months before evaluation. Hormone concentra-
tions are the result of oscillatory secretions, influenced both by 
time of day and by period of the menstrual cycle [38-40]. There-
fore, single measurements of hormone concentrations are char-
acterized by high biological variation [40]. In paper [6], we applied 
20 minutes LH measurements to further characterize 24h changes 
in LH secretion during pioglitazone treatment as described previ-
ously by Veldhuis [41;42]. This method is time consuming and can 
not be applied in the daily clinic. The gold standard method for 
measuring total testosterone is mass spectrometry, whereas com-
mercially available direct assays generally overestimate the ster-
oid concentration [43;44]. Ether extraction followed by specific 
radio immunoassay can be applied to avoid over estimation of 
steroid hormones [45]. This method shows close correlation with 
the determination of testosterone levels by using mass spectrom-
etry [46]. In this thesis, extraction methods as described by 
Lykkesfeldt were therefore applied when possible [46].  
 
Evaluation of insulin sensitivity 
The euglycemic hyperinsulinemic clamp is considered the gold 
standard for the establishment of insulin sensitivity [47]. The 
euglycemic clamp method assesses whole-body insulin-mediated 
glucose disposal.  The clamp method was used in paper [6], as we 
aimed for a precise characterization of degree and mechanism of 
insulin resistance. However, the clamp method is time-consuming 
and requires technical expertise not widely available.  
Fasting insulin and homeostasis assessment model (HOMA) are 
easily applied in daily clinical practice as measures of insulin re-
sistance. Fasting insulin levels correlate well with the measures of 
insulin sensitivity from clamp studies [48]. However, fasting insu-
lin levels are the result of both insulin secretion and metabolism. 
Fasting insulin therefore do not provide accurate information on 
insulin sensitivity in individuals with beta-cell dysfunction. Espe-
cially when glucose levels are high as in T2D, insulin secretion is 
stimulated, thus resulting in higher insulin levels. HOMA, defined 
as fasting insulin*fasting glucose/22.5, has been shown to corre-
late better with insulin resistance than fasting insulin in some 
studies [49].  
 
Evaluation of body composition 
Weight and BMI are the simplest methods for the establishment 
of total body fat. These variables are inexpensive, easily applied in 
daily praxis, and offer a minimum of discomfort for the patient. 
However, due to the importance of fat distribution for metabolic 
and hormonal variables, measurements of body composition are 
needed as well as measures of total body fat. Waist circumfer-
ence is a good estimate of abdominal fat [50], and can be applied 
in the daily clinic.   
DXA scans offer the opportunity for establishing total body fat 
and make it possible to estimate abdominal and extremital fat 
mass [51;52]. However, the method is limited by the lack of ability 
to distinguish intra-abdominal fat mass from subcutaneous fat 
mass. Recent studies, however, suggested that subcutaneous ab-
dominal and intra-abdominal fat have similar adverse effects on 
insulin resistance [53].  
Aims of thesis 
In the present thesis, the diagnosis, pathogenesis, risk factors, 
and medical intervention in hirsutism and PCOS are discussed. 
The thesis includes cross sectional data and results from two ran-
domized controlled studies.  
The aims of the present thesis can be grouped under these head-
ings:  
 
Diagnostic strategies in patients with hirsutism and PCOS  
 To evaluate the prevalence of endocrine diseases in hir-
sutism [1] 
 To establish the prevalence of T2D and to discuss the 
use of HbA1c and OGTT [1;5] 
 To evaluate the use of ACTH tests [2] 
Pathogenic mechanisms in PCOS  
 To evaluate mechanisms of insulin resistance [6] 
 To evaluate adrenal activity [2] 
 To investigate the importance of the following inflam-
matory markers in PCOS 
o Adiponectin [3;7] 
o Ghrelin [3] 
o Leptin [3] 
o hsCRP and IL-6 [8] 
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o Cardiovascular risk markers and sCD-36 [8] 
o Prolactin [4] 
 
Medical intervention 
To investigate the effect of different treatment principles in PCOS 
 Oral contraceptives [9] 
 Insulin sensitizing treatment [6-9] 
Evaluation of endocrine diseases in hirsutism and 
PCOS  
Hirsutism may be a manifestation of Cushing’s syndrome, andro-
gen producing tumors, acromegaly, or late onset adrenogenital 
syndrome (NC-AGS). Thyroid diseases, prolactinomas, and early 
menopause are associated with menstrual disturbances and 
should not be confused with PCOS. According to the Rotterdam 
criteria [12], PCOS is a diagnosis of exclusion. PCOS and idiopathic 
hirsutism are treated with OCP, lifestyle intervention, metformin, 
and cosmetic treatment, whereas other treatment modalities are 
needed in patients with endocrine diseases. Patients with andro-
gen producing tumors and Cushing’s Syndome need surgery. Hir-
sutism and PCOS has a prevalence of more than 10% in reproduc-
tive aged women and menstrual irregularities are often occurring, 
especially in women < 20 years [20;54]. General practitioners, gy-
necologists, and endocrinologists therefore need reliable screen-
ing tools to exclude endocrine diseases in the daily clinic.   
The optimal screening programme for patients with hirsutism/ 
suspected PCOS has been debated [54-56]. In Paper [1], we ap-
plied a standardized evaluation program in all newly referred pa-
tients with hirsutism/ PCOS. The evaluation programme included 
clinical evaluation, fasting blood samples during follicular phase, 
transvaginal US, ACTH test, and OGTT [1]. In our population 5/340 
= 1.5% patients were diagnosed with serious endocrine diseases 
[1]. This prevalence corresponded to results in previous studies 
[57-60]. The overall prevalence of endocrine diseases was 5.4% in 
a total of 7563 patients of mixed ethnical origin and diverse refer-
ral diagnoses of hyperandrogenaemia, anovulation, and/or PCOS 
[20]. 
CYP21 defects are autosomal recessive disorders, causing de-
creased cortisol secretion by the adrenals due to decreased activ-
ity of the 21-hydroxylase enzyme. The overall prevalence of NC-
AGS in patients with hyperandrogenaemia is 1.3% [20], but varies 
according to the examined population. Symptoms in patients with 
NC-AGS and PCOS are similar and the two conditions can not be 
distinguished based on clinical symptoms alone. Patients with NC-
AGS all had elevated basal 17-hydroxyprogesterone (17OHP) 
[1;57-60]. Some studies found CYP21 defects in patients with only 
modesty increased 17OHP levels and therefore the cut-off for 
17OHP, above which 21-hydroxylase defects should be excluded, 
is most often set at 6-10 nmol/l [20;61]. This level corresponds to 
17OHP levels in luteal phase and therefore 17OHP measurements 
should be repeated in patients with near-normal 17OHP levels be-
fore ordering a confirmatory ACTH test.  
It was previously suggested that patients with PCOS had relative 
dopamine deficiency, which could lead to abnormal GnRH pulsa-
tility, increased LH secretion, and a tendency to increased prolac-
tin levels [62]. The majority of studies could not confirm this hy-
pothesis [63], and it now generally recognized that patients with 
PCOS do not have increased prolactin levels. In contrast, we 
found that prolactin levels were significantly decreased in pa-
tients with PCOS vs. controls [4] and could be associated with 
metabolic risk in PCOS. We found 8/340 patients with prolactin 
above reference interval and 1/8 patients was diagnosed with a 
microprolactinoma [1]. Our finding of low prevalence of prolacti-
nomas in a population with hyperandrogen symptoms was in ac-
cordance with other studies [58;60]. Therefore, prolactinomas 
seem to occur only rarely in hirsute patients. Hyperprolactinemia 
should be treated with dopamine agonists and it is therefore rec-
ommended that patients with increased prolactin levels should be 
referred to an endocrine department for further evaluation and 
treatment [20;64].  
 
Table 2. Initial evaluation of hirsute patients  
 
Gonadotropins are secreted in a pulsatile pattern, and therefore 
an increased LH/FSH ratio is no longer part of the PCOS diagnosis 
[12]. The measurement of LH and FSH is however relevant to ex-
clude premature ovarian failure or central amenorrhea.  
Androgen producing tumors are often rapidly progressing and 
surgery is the first line treatment. In the literature, women diag-
nosed with androgen producing tumors experienced rapid pro-
gression of hyperandrogen symptoms during a rather short time 
period and the medical history in combination with the clinical 
appearance raised the suspicion of androgen producing tumors 
[1;65]. The cut-off limit for total testosterone above which an an-
drogen producing tumor should be excluded is usually set as 
more than two times above the upper reference limit [1;12;16]. It 
is, however, important that a reliable method of testosterone 
measurement is used. Commercially available direct assays gener-
ally overestimate the steroid concentration [43;44]. Over-estima-
tion of androgen levels increase the risk of ordering unnecessary 
ultrasound and magnetic resonance imaging in healthy women 
and incidentalomas may be diagnosed [66].  
Cushing’s syndrome is caused by excess glucocorticoids produced 
by the adrenal cortex. ACTH levels are used to discriminate be-
tween adrenal or pituitary/ectopic tumours. One patient diag-
nosed with Cushing’s syndrome could be diagnosed using medical 
history and clinical examination [1]. During the study inclusion 
Clinical exami-
nation  
Height, weight, waist, blood pressure, degree of hir-
sutism 
 Transvaginal US (PCO and endometrial thickness) 
 
Blood samples  Total testosterone, sex hormone binding globulin 
(free testosterone calculated)  
 LH, FSH  
 Prolactin 
 17-OHP 
 HbA1c, lipids  
 TSH 
Secondary 
evaluation 
Suspected Cushing’s syndrome: 24-h urinary corti-
sol, short dexamethasone test or midnight cortisol.   
 MR/CT of the adrenals when testosterone is more 
than two times increased 
 OGTT acromegaly in patients with clinical symptoms 
of acromegaly 
 
Patients should be evaluated following >3 months OCP pause and in 
follicular phase 
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time, 25 patients at the department were diagnosed with Cush-
ing’s syndrome. These patients were all referred on account of 
hypertension and/ or suspicion of Cushing’s syndrome. The ma-
jority of androgen producing adrenal tumors co-secretes cortisol, 
which may explain why many patients do not primarily present 
with PCOS-associated symptoms [67]. Only 6% of adrenal tumors 
secrete androgens alone [67]. 
 
In conclusion, patients with regular menses during a period of 6 – 
12 months are unlikely to suffer from serious endocrine diseases. 
Most often, patients with irregular menses have PCOS. General 
practitioners can perform major part of the evaluation program 
and will be able to exclude serious endocrine diseases requiring 
treatment at a specialist center. Table 2 includes a suggested 
evaluation program in premenopausal patients referred with hir-
sutism and/or PCOS. The use of HbA1c and metabolic screening 
will be discussed further below.   
Ovarian and adrenal androgen production in PCOS 
Patients with PCOS have supra-normal androgen responses to a 
short-time GnRH stimulation test suggesting overproduction of 
ovarian androgens [68;69]. Furthermore, adrenal suppression 
with dexamethasone is associated with persisting hyperandro-
genemia in PCOS [70;71]. The LH pulse amplitude and pulse fre-
quency is increased and irregular in PCOS [72]. When the concen-
tration of LH increases relative to FSH, the ovarian androgen 
production by the theca cells increases and the development of 
the oocyte is disturbed [72]. Increased LH pulse frequency in 
PCOS could be due to increased pulse frequency of GnRH [73]. A 
primary hypothalamic defect could therefore be the primary 
cause of increased LH levels in PCOS [74]. Due to the pulsatile se-
cretion pattern of LH, a random LH concentration measurement is 
of minor clinical value [41].  
Increased ovarian androgen production is not only the result of 
increased LH stimulation. In vitro studies on theca cells from poly-
cystic ovaries showed increased conversion of androgen precur-
sors to testosterone both basally and after gonadotropin stimula-
tion [75;76]. These findings support that theca cells from patients 
with PCOS have constitutional defects, which lead to increased 
ovarian androgen production [73].  
 
DHEAS is mainly produced in the adrenal glands and therefore in-
creased DHEAS can be used as a marker of increased adrenal ac-
tivity in PCOS [77]. DHEAS levels are increased in 20-30% patients 
with PCOS [78]. Levels of DHEAS decrease with age independent 
of PCOS status and race [78;79]. Brothers of PCOS patients have 
increased DHEAS levels suggesting that adrenal hyperactivity may 
be an inherited trait of PCOS [80]. Several studies described simi-
larities between the hormonal secretion pattern in females with 
precocious pubarche and PCOS patients and precocious pubarche 
and adrenarche was a forerunner of PCOS in some patients 
[81;82]. Ibanez suggested that increased adrenal activity could be 
caused by intrauterine stress causing precocious pubarche and 
later on PCOS [83].  
About 25-50% of PCOS patients have increased ACTH-stimulated 
17OHP responses [2]. Initial studies reported that more than 20% 
of hyperandrogen patients were carriers of 21-hydroxylase de-
fects compared to a prevalence of less than 5-10% in the back-
ground population [84;85]. It was therefore suggested that CYP21 
heterozygosity could be an important pathogenic factor in PCOS 
despite the recessive mode of inheritance [86]. To confirm this 
hypothesis we included 337 hirsute patients, sequenced the 
whole CYP21 gene, and performed additional ACTH tests measur-
ing cortisol and 17OHP levels [2]. In our study population, CYP21 
carrier status in hirsute patients was similar compared to controls 
and cortisol levels were significantly increased [2]. These findings 
therefore supported that increased 17OHP levels in hirsutism 
were caused by increased adrenal activity and not by CYP21 de-
fects [2]. This hypothesis is supported by studies measuring signif-
icantly increased ACTH-stimulated cortisol levels in PCOS patients 
vs. controls [2;87;88]. 
 
Different mechanisms may lead to increased hypothalamic-pitui-
tary-adrenal (HPA) activity in PCOS. Previous studies reported in-
creased urinary excretion of cortisol [89-92] and androgen [89-91] 
metabolites in PCOS patients compared with controls. Increased 
adrenal drive in PCOS could therefore be explained by increased 
cortisol turnover, whereas levels of cortisol in serum are usually 
normal in PCOS [93;94]. 
The enzyme 5α-reductase is present in the dermal papillae and 
mediates the conversion of testosterone to the more active an-
drogen dihydrotestosterone. Dermal 5α-reductase activity is in-
creased in PCOS [95;96]. High dihydrotestosterone levels increase 
terminal hair growth in the dermal papilla and therefore, 5α-re-
ductase inhibitors can be used for the treatment of hirsutism [97]. 
Increased hepatic 5α-reductase activity in PCOS patients could be 
a mechanism for increased cortisol metabolism possibly leading 
to hyperactivity of the hypothalamic-pituitary-adrenal axis in 
PCOS [89;92;98]. Therefore, PCOS could be caused by increased 
5α-reductase activity in skin and liver [89]. Supporting that a 
more general increased 5α-reductase activity may be important 
in PCOS, ovarian 5α-reductase activity was increased in polycystic 
ovaries [99]. We found that 5α-reductase activity decreased dur-
ing pioglitazone treatment, which supported that 5α-reductase 
activity could be associated with insulin resistance in PCOS [100]. 
As an alternate mechanism for increased cortisol turnover, Stew-
art et al. furthermore demonstrated impaired reactivation of cor-
tisol by 11β-hydroxysteroid dehydrogenase 1 in PCOS patients 
[89;93].  
Insulin resistance 
The physiologic effect of insulin is to stimulate glucose uptake in 
muscle and adipocytes and to suppress hepatic glucose produc-
tion. Insulin suppresses lipolysis and therefore levels of FFA de-
crease. Insulin resistance is defined as a decreased ability of insu-
lin to mediate the metabolic actions on glucose and lipid 
metabolism. Therefore, increased amounts of insulin are required 
to achieve a given metabolic action. Insulin resistance is therefore 
characterized by increased levels of insulin as long as the pancre-
atic beta-cell function is intact [101]. The measurement of insulin 
resistance is described in the Methods section.  
 
The link between PCOS and insulin resistance was first described 
in 1980 by Burghen [102]. It is now well-established that more 
than 50% of PCOS patients are insulin resistant [103]. Insulin re-
sistance is closely associated with BMI, but is also present in nor-
mal weight patients with PCOS [1]. The exact mechanism for insu-
lin resistance in PCOS is still unknown. Patients with PCOS have 
similar insulin receptor amount and affinity compared with con-
trols and therefore insulin resistance is probably mediated 
through changes in the insulin receptor-mediated signal transduc-
tion cascade [6;104]. Impaired insulin-mediated glucose disposal 
in PCOS compared to controls was described in previous studies 
[6;105-109]. Furthermore, oxidative and non-oxidative glucose 
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metabolism was impaired in PCOS in studies using indirect calo-
rimetry and clamp techniques [6;107]. In these studies, insulin 
stimulated non-oxidative glucose metabolism was more severely 
impaired than oxidative glucose metabolism supporting de-
creased glycogen synthase activity in PCOS [6]. Impaired glycogen 
synthase activity was confirmed by studies on muscle biopsies 
from PCOS patients [110]. In muscle biopsies, patients with PCOS 
had significantly impaired insulin signalling through Akt and 
AS160 and impaired insulin-stimulated activity of glycogen syn-
thase activity compared to controls [15;110]. Some PCOS patients 
had increased serine phosphorylation of insulin receptor β, but 
also distant parts of the insulin receptor cascade were affected 
[15;110-112]. 
Insulin resistance in PCOS may be inherited or could be due to 
adaptive mechanisms such as obesity and hyperandrogenism. 
These mechanisms were further evaluated in cultured myotubes 
obtained from insulin resistant patients with PCOS and controls 
[113;114]. Defects in insulin action that persist in cells removed 
from the in vivo environment for several passages suggest that 
these changes are the results of mutations in genes regulating 
these pathways. As recently reviewed [101], data on insulin ac-
tion in myotubes from patients with PCOS vs. controls were con-
flicting. We found that glucose uptake and oxidation, glycogen 
synthesis and lipid uptake were comparable between patients 
with PCOS and controls along with comparable activity of the mi-
tochondria [113;114]. These results suggested that insulin re-
sistance in PCOS is the result of adaptive rather than inherited de-
fects in the insulin signalling cascade.   
 
Insulin secretion from the pancreatic beta-cell increases to com-
pensate for insulin resistance. The hyperinsulinemia in PCOS may 
therefore be an adaptive mechanism of the pancreatic beta-cells 
to insulin resistance. The relationship between insulin secretion 
and insulin sensitivity is usually a constant hyperbolic function, 
which is described as the disposition index [101]. The disposition 
index predicts the risk of T2D. Pancreatic beta-cell dysfunction is 
required for the development of T2D. Dysglycemia develops 
when the pancreatic beta-cell is no longer able to secrete suffi-
cient insulin to meet the increased requirements in insulin re-
sistance. Increased risk of T2D in PCOS suggests impaired beta-
cell function as well as insulin resistance. Several studies found 
decreased disposition index in patients with PCOS vs. controls 
[115;116]. However, other studies found increased [107;117] 
beta-cell responses to glucose stimulation in PCOS and the degree 
of beta-cell dysfunction in PCOS remains to be established.  
In our study, the disposition index was unchanged during pioglita-
zone treatment suggesting unchanged beta-cell function [6].  
Impaired hepatic insulin clearance also results in hyperinsuline-
mia [6;108;109]. Some studies measured increased insulin/C-pep-
tide ratio in PCOS suggesting decreased hepatic extraction of in-
sulin in PCOS [101].  
Insulin resistance and hyperandrogenemia in PCOS 
Since the first discovery of insulin resistance in PCOS patients, the 
possible link between hyperinsulinemia and high androgen levels 
has been investigated. Insulin may stimulate androgen production 
in ovaries and adrenals and/or hyperandrogenemia may promote 
insulin resistance.  
Insulin receptors are present in normal and in polycystic ovaries 
[101]. Insulin in synergy with LH stimulated p450c17 activity in 
ovaries and adrenals and resulted in increased androgen produc-
tion [118;119]. Studies supported that the theca cells from pa-
tients with PCOS are more responsive to the androgen stimulating 
actions of insulin than normal ovaries [101]. Therefore, insulin 
may act as a co-gonadotropin to increase androgen synthesis 
from theca cells. Furthermore, hyperinsulinemia decreases SHBG 
production by the liver and through this mechanism free testos-
terone levels increase [120]. Low SHBG levels predicted the diag-
nosis of PCOS [121] and correlated with low insulin sensitivity 
during euglycemic hyperinsulinemic clamps [122].   
The relation between hyperinsulinemia and hyperandrogenemia 
in PCOS was further investigated in studies using diazoxide treat-
ment to inhibit insulin secretion [123]. Diazoxide treatment was 
followed by decreased total and free testosterone levels and in-
creased SHBG levels [123]. Furthermore, treatment with metfor-
min and glitazone treatment was associated with higher ovulation 
rates [35;124;125]. These findings supported that hyperinsuline-
mia and insulin resistance are pathogenic factors in PCOS. Sug-
gesting a more complex interaction between androgens and insu-
lin sensitivity, glitazone treatment was associated with improved 
ovarian function and increased SHBG levels [6;126-128], but un-
changed testosterone levels and FG score [6;126]. Furthermore, 
the exact mechanism of action of metformin is unknown which 
complicates interpretation of studies using metformin treatment. 
The effect of metformin on insulin sensitivity is probably indi-
rectly mediated via impaired hepatic gluconeogenesis [129]. In a 
recent study, metformin decreased hepatic glucose output and 
improved glucose effectiveness without changing insulin sensitiv-
ity [129]. Metformin treatment is often followed by slight weight 
loss, which may improve insulin sensitivity [9;35]. 
 
The association between insulin resistance and adrenal activity in 
PCOS is not clear. DHEAS was not associated with fasting insulin in 
cross sectional studies [1;2;77;130]. The results of studies using 
insulin sensitizing treatment have been conflicting as some re-
ported unchanged adrenal androgen levels [100;131-133], 
whereas other studies found decreased adrenal activity during 
metformin [134;135] or PPAR-γ agonist treatment [126;136;137]. 
We found decreased 5-α-reductase activity during pioglitazone 
treatment in PCOS, which could suggest decreased cortisol me-
tabolism and therefore decreased HPA drive [100].  
 
Testosterone may stimulate insulin resistance directly or indi-
rectly. Testosterone applied in supra-physiological doses in 
women was directly followed by insulin resistance evaluated by 
euglycemic clamp studies [138]. Furthermore, high testosterone 
levels may promote abdominal obesity, which may indirectly in-
duce insulin resistance [17]. PCOS phenotypes with hyperandro-
genemia were more insulin resistant than phenotypes without hy-
perandrogenemia, which further supported the importance of 
hyperandrogenemia for insulin resistance in PCOS [138].  
The effects of decreased androgen levels on insulin resistance 
were evaluated after androgen inhibition with GnRH agonists 
[138;139] or ovarian wedge resection [140;141]. In the majority 
of studies, insulin sensitivity however, did not increase despite 
decreased androgen levels.  
Cyproterone acetate and OCP inhibit androgen levels, but were 
associated with increased insulin resistance rather than increased 
insulin sensitivity [142-144]. Adverse effects of OCP could how-
ever be due to the progesterone component [145] as anti-andro-
gen treatment with flutamide was followed by increased insulin 
sensitivity and reduced inflammatory markers [146]. Increased in-
flammatory markers and unchanged central obesity were ob-
served in PCOS during medical intervention with OCP, which may 
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explain that decreased androgen levels did not improve insulin 
sensitivity in PCOS [9].   
Diabetes risk in PCOS  
Nearly 50% of PCOS patients fulfill the criteria of the metabolic 
syndrome and PCOS is associated with increased risk of diabetes 
[1;147]. The prevalence of diabetes in cross sectional studies was 
1.5-10% and the prevalence of impaired glucose tolerance (IGT) 
was 10-36% [1;147;148]. Using OGTT, we found that the preva-
lence of previously undiagnosed diabetes was 4.7% resulting in a 
total diabetes prevalence of 6.6%. The median BMI of our study 
cohort was 27 kg/m2 [1]. 13/14 patients diagnosed with diabetes 
in our study population was overweight supporting that obesity is 
an important predictor of diabetes in PCOS [1]. Based on available 
studies it is currently estimated that PCOS is associated with 5-8 
times increased diabetes risk compared to age and weight-
matched controls [103]. 
Until recently it was recommended that OGTT should be per-
formed as a baseline screening in all PCOS patients, but fasting 
plasma glucose could be applied where OGTTs were not available 
[12;14]. In daily practice the performance of OGTT is inconvenient 
and time consuming because the patient has to be seen in a fast-
ing state and the test duration is two hours. There are considera-
ble intra-individual variations in fasting and 2 hour glucose levels, 
which may lead to misclassification of abnormal glucose tolerance 
[149;150]. HbA1c is a widely used marker of chronic glycemia and 
reflects the average blood glucose levels over a two- to three-
month period [151]. HbA1c has higher repeatability than fasting 
glucose and can be assessed in the non-fasting state [151]. HbA1c 
may however be affected by genetic, hematologic, and illness-re-
lated factors [151;152]. Recently, HbA1c ≥ 6.5% was applied as 
the cut-off point for diagnosing T2D in asymptomatic patients 
[151]. The cut-off point for HbA1c was based on the established 
association between HbA1c and microvascular disease [151].  
In our population of patients with PCOS, HbA1c had a low sensi-
tivity of 35% for the diagnosis of T2D when OGTT was used as the 
gold standard for the diagnosis of diabetes [5]. However, the 
specificity of HbA1c for the diagnosis of diabetes was high and the 
more severe cases of T2D established by the OGTT were also 
identified by the HbA1c method. These results were in agreement 
with recent studies in Turkish [153] and Austrian [154] popula-
tions with PCOS and supported that HbA1c can not be used to di-
agnose diabetes when OGTT is considered the gold standard test. 
Celic and Lerchbaum therefore concluded that OGTT should be 
performed in all patients with PCOS [153;154]. This conclusion 
was based on the importance of diagnosing diabetes in an early 
stage to make sure that treatment with metformin and lifestyle 
intervention was initiated [153;154]. Our findings supported that 
increased HbA1c levels could be used as a marker of cardiovascu-
lar risk in PCOS [5]. Increasing HbA1c was associated with higher 
waist, BMI, and a more adverse lipid profile [5]. These results 
were supported by studies in non-PCOS populations where HbA1c 
and fasting glucose levels were similarly associated with risk of di-
abetes, but HbA1c was more strongly associated with risk of car-
diovascular disease and death from any cause than fasting glu-
cose [155]. Population based studies found that increasing HbA1c 
levels within the reference range were associated with cardiovas-
cular disease [155-157]. Different study populations may there-
fore be identified when HbA1c and glucose levels are applied for 
the diagnosis of diabetes.  
At present, the indication for performance of OGTT in patients 
with PCOS is unclear. Previous guidelines recommended that 
OGTT should be performed in all patients [14], whereas recent 
guidelines suggested that OGTT should be performed in high risk 
patients with BMI > 30 kg/m2, age > 40 years, a history of GDM, or 
a family history of T2D [1;153;154]. Up to 30% patients with PCOS 
and T2D according to OGTT would however not be diagnosed if 
these criteria were applied [154]. In our study, 1/13 patients diag-
nosed with diabetes had BMI < 25 kg/m2. In the studies by Lerch-
baum [154] and Vribkova [158], 0/298 and 1/104 PCOS patients 
with BMI < 25 kg/m2 were diagnosed with diabetes during OGTT, 
respectively. Therefore, if the aim is to diagnose T2D, the value of 
performing OGTT in normal weight patients with PCOS seems to 
be limited. The importance of diagnosing pre-diabetes is currently 
discussed. Pre-diabetes is defined as blood glucose levels higher 
than normal but below diabetes thresholds. Pre-diabetes can be 
diagnosed in patients with impaired fasting glucose (fasting glu-
cose ≥ 6.1 mmol/l and < 7.0 mmol/l), impaired glucose tolerance 
(2 hour glucose levels ≥ 7.8 mmol/l and < 11.0 mmol/l), and/or 
HbA1c 5.7 – 6.4% [159]. It is estimated that 5-10% individuals 
with pre-diabetes convert to diabetes/ year and up to 70% indi-
viduals with pre-diabetes will develop diabetes [159]. Pre-diabe-
tes should be treated with life style intervention, but treatment 
with metformin also postpones the development of diabetes 
[159]. It remains to be determined whether the performance of 
OGTT is relevant with the aim of diagnosing pre-diabetes or as a 
tool for estimating prognosis and/or choice of treatment modality 
in patients with PCOS. Whether HbA1c is superior to OGTT re-
garding long term metabolic and cardiovascular risk in PCOS re-
mains to be established in future studies. 
Central obesity and fat metabolism in PCOS 
Approximately 75% PCOS patients are overweight and central 
obesity is seen in both normal and overweight PCOS patients 
[160-162]. Increased fat ingestion in PCOS patients vs. controls 
was found in some studies [163;164], but could not be repro-
duced by others [165]. Ghrelin secretion following meals were 
less suppressed in PCOS compared to controls, which suggesting 
impaired appetite regulation [166]. The prevalence of eating dis-
orders was nearly 40% in women presenting with hirsutism [167], 
and conversely, PCOS was overrepresented in bulimic women 
[168]. The metabolic rate is not decreased in PCOS patients 
[6;169;170] and randomized studies showed no differences in the 
ability to loose weight between PCOS patients and weight-
matched controls on the same diet [171;172]. In previous studies, 
decreased quality of life in PCOS was associated to increased 
body weight [173]. 
 
Visceral adiposity is associated with insulin resistance and in-
creased morbidity [174], suggested to be at least partly mediated 
via a state of low-grade inflammation [175;176]. In PCOS, in-
creased fat mass is associated with hyperandrogenism, irregular 
ovulations, and reduced fertility [16]. The adipose tissue produces 
and releases a number of bioactive proteins, collectively referred 
to as adipokines [177]. Except for leptin and adiponectin, adi-
pokines are not exclusively produced by adipocytes, but are pri-
marily secreted by adipose tissue-resident macrophages [178]. In 
obesity, the number of adipose tissue-resident macrophages is in-
creased in both subcutaneous abdominal and visceral adipose tis-
sue [179;180] and the circulating mononuclear cells are more in-
flammatory active [175]. Increased adipokine secretion predicts 
the metabolic syndrome and increases the risk of diabetes. We 
and others investigated the importance of several adipokines in 
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PCOS and the effects of medical intervention. Some of these adi-
pokines are mentioned below. High inflammatory activity in PCOS 
could be due to central obesity and/or increased testosterone 
levels. A close relation between inflammation and testosterone 
levels is supported by intervention studies using simvastatin [181] 
and flutamide in PCOS [146]. In these studies simvastatin de-
creased androgen levels [181] and flutamide decreased markers 
of inflammation [146].  
 
Levels of free fatty acids (FFA) are increased in PCOS both in the 
fasting state and during the hyperinsulinemic clamp period 
[6;117;182]. FFAs influence glucose metabolism as they compete 
with glucose uptake in peripheral tissues [183]. Chronically ele-
vated FFA levels increase gluconeogenesis and insulin resistance 
while insulin secretion is impaired [184;185]. The positive effect 
of PPAR-γ agonists on insulin sensitivity may be mediated through 
improved lipid metabolism with decreased FFA levels and de-
creased visceral fat volume [36;37]. Thiazolidinedione treatment 
in PCOS was associated with unchanged [6;186;187] or increased 
[128] BMI. Body composition evaluated by DXA-scan [188] and 
WHR [128;187;188] was unchanged during thiazolidinedione 
treatment in PCOS. The effects of glitazone treatment on lipid 
metabolism in PCOS were evaluated in randomized studies using 
insulin infusions of 40 [6], 80 [126], and 300 mU/m2 min [128]. In 
these studies, measures of insulin sensitivity and glucose metabo-
lism significantly improved, whereas improved insulin stimulated 
suppression of FFA levels [6] and decreased lipid metabolism 
[6;126] was reported in two studies. Pioglitazone treatment im-
proved lipid profiles in patients with insulin resistance and/or T2D 
[189;190], but not in PCOS [8;187;191]. Improved lipid profiles 
during glitazone treatment in patients with T2D suggest that the 
effect on lipid profile may be related to reduced blood glucose 
levels [189].  
Limited data are available on the effects of metformin and OCP 
on regional fat mass in PCOS. In our study, a 3rd generation OCP 
was associated with a median weight gain of 1.2 kg, which was 
evenly distributed on the upper and lower body regions [9]. 
Changes in testosterone levels were not associated with changes 
in fat distribution during bivariate regression analyses. Therefore, 
our data did not support that the android fat distribution was im-
proved during treatment with OCP in PCOS. In previous six-
months studies, weight was unchanged in PCOS [192;193] and 
non-PCOS populations [194] during treatment with different gen-
eration OCPs. Previous studies supported that OCP may improve 
LDL, total cholesterol, and HDL, whereas TG levels increased 
[195]. 
In a recent review, the effect of metformin on weight loss was 
limited in PCOS [35], but the study duration of included studies 
was six months or less, which could be too short to document ef-
fects on body composition measures. We found a median weight 
loss 1.6 kg after 6 months and 3.0 kg after 12 months treatment 
with metformin mono-therapy, which was not affected by BMI at 
study inclusion [9]. Therefore normal weight patients with PCOS 
could also benefit from metformin treatment. Our data support 
that weight loss during metformin treatment in PCOS is not due 
to initial side effects alone, but the exact mechanism for im-
proved body composition could not be concluded. Metformin 
treatment  inhibited gastric ghrelin secretion in vitro, which could 
suggest improved appetite regulation [196]. We found no signifi-
cant changes in adiponectin levels during metformin treatment 
[197] and the effect of metformin treatment on ghrelin secretion 
needs further testing in PCOS. The importance of weight loss for 
treatment of PCOS is further discussed in the Treatment section. 
Several studies supported that metformin treatment is associated 
with improved lipid profile with decreased LDL and TG levels, and 
increased HDL without changes in total cholesterol levels [35].     
The metabolic syndrome in PCOS 
The elements of the metabolic syndrome in PCOS are given below 
[12]:  
 Waist ≥ 88 cm 
 Impaired glucose tolerance 
 Blood pressure >130/85 mmHg 
 HDL <1.3 mmol/l 
 TG >1.7 mmol/l 
A high percentage of PCOS patients have abnormal lipid profiles 
including increased total cholesterol, TG, and LDL, whereas HDL 
levels are decreased [8;198]. It was estimated that 70% women 
with PCOS had borderline or high lipid levels [199]. As recently re-
ported, dyslipidemia may depend on ethnicity [200] and age [79] 
in PCOS.  
 
It is generally recommended that patients with PCOS are 
screened for the elements of the metabolic syndrome. Whether 
this screening should include other metabolic risk markers re-
mains to be determined. 
Some of the most important metabolic risk markers in PCOS are 
presented below. Some of these markers may add information on 
different metabolic aspects in PCOS such as inflammatory activity 
and cardiovascular risk. 
Adiponectin  
Adiponectin is the most abundant secreted protein and is se-
creted exclusively by the adipose tissue [201]. Adiponectin secre-
tion is down regulated in obesity [202]. Low circulating levels of 
adiponectin was associated with increased risk for insulin re-
sistance and T2D [203]. The mechanisms, by which adiponectin 
affect insulin sensitivity, are not fully clarified. Animal and in vitro 
studies found that recombinant adiponectin stimulated muscular 
and hepatic glucose uptake, decreased hepatic gluconeogenesis, 
and promoted FFA oxidation in skeletal muscle [201;204;205]. 
Therefore, adiponectin reduced TG levels and increased insulin 
sensitivity. Low adiponectin levels were associated with impaired 
insulin-stimulated oxidative and non-oxidative glucose metabo-
lism in healthy individuals and in T2D, suggesting that low plasma 
adiponectin levels contribute to impaired glucose transport and 
glycogen synthesis [206-209].   
Adiponectin levels are decreased in PCOS patients compared to 
weight matched controls [3;210] and inversely correlate with fast-
ing insulin [3;211], central fat mass [3;7], and whole body- and 
non-oxidative glucose metabolism [7;212]. Adiponectin correlated 
inversely with lipid oxidation and FFA levels during insulin stimu-
lation in PCOS [7]. This indicates that adiponectin may improve 
the capacity to switch from lipid to glucose metabolism and to 
store glucose as glycogen in response to insulin [7].  Adiponectin 
was positively associated with ghrelin and inversely associated 
with leptin [3]. 
Total testosterone was both positively and negatively associated 
with adiponectin in previous studies. We found that total testos-
terone was positively associated with adiponectin levels in PCOS, 
which remained significant after correcting for WHR and total fat 
mass [3]. In another study population, total testosterone was in-
versely associated with adiponectin [7]. In these studies, no signif-
icant associations were found between free testosterone levels 
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and adiponectin [3;7]. The results of these studies were included 
in a meta-analysis, concluding that total testosterone levels were 
not associated with adiponectin [210]. In agreement with this, in-
creased insulin sensitivity was associated with increased adi-
ponectin levels despite unchanged testosterone [7] and changes 
in testosterone levels were not associated with changes in adi-
ponectin [7]. Therefore, factors other than testosterone may be 
important for adiponectin secretion in PCOS.  
 
Adiponectin may have direct effects on ovarian function. Adi-
ponectin receptors are found in the ovaries and in the endome-
trium [201]. Theca cells in patients with PCOS had decreased ex-
pression of adiponectin receptors compared to healthy ovaries 
[213]. Adiponectin stimulation was associated with decreased 
ovarian androgen production [213]. These findings support im-
portant relations between obesity, adiponectin, and hyperandro-
genism in PCOS. Increased testosterone levels in obese patients 
with PCOS could be mediated indirectly by decreased adiponectin 
levels.   
 
The beneficial effects of PPAR-γ agonist treatment on insulin sen-
sitivity may be caused in part by the ability to increase adiponec-
tin levels [214]. In PCOS, adiponectin levels increased during 
PPAR-γ agonist treatment [7;212;215]. Following pioglitazone 
treatment, increased adiponectin levels were associated with in-
creased insulin-stimulated glucose metabolism and decreased li-
pid oxidation [7]. Weight and fat mass measures were unchanged 
during pioglitazone treatment, which supported that changes in 
insulin sensitivity predicted adiponectin levels [7]. In contrast to 
findings with glitazones, adiponectin levels were unchanged dur-
ing metformin treatment [35;197;216;217]. We found that body 
composition improved during 12 months randomized treatment 
with metformin and/or OCP treatment, but changes in adiponec-
tin levels were comparable in the three treatment arms [197]. It 
was reported that a weight loss more than 10% was needed to in-
duce significant increases in adiponectin [218]. In agreement with 
this, a moderate weight loss of 3.8% during lifestyle intervention 
did not change adiponectin levels in PCOS [219]. We found un-
changed HOMA-levels during metformin treatment [9]. These 
findings could suggest that increased insulin sensitivity is a more 
important mechanism for increased adiponectin secretion than 
smaller improvements in body composition. The effects of physi-
cal activity on adiponectin secretion in PCOS should be further 
evaluated.  
 
Adiponectin circulates in different polymer-complexes classified 
as high-molecular weight multimers, medium-molecular weight 
hexamers, and low-molecular weight trimers [220]. It was sug-
gested that the effect of adiponectin on insulin-stimulated glu-
cose metabolism was mediated primarily by the high-molecular 
weight form of adiponectin [221-224]. In these studies, only high-
molecular weight adiponectin showed a similar close association 
with progression to T2D [224], level of insulin resistance 
[221;222], and the presence of the metabolic syndrome [222] as 
total adiponectin. Data in patients with PCOS were conflicting. We 
found weaker correlations between measures of insulin-stimu-
lated glucose metabolism and absolute or relative levels of high-
molecular weight adiponectin than with total adiponectin [7]. 
These data suggested that no further information is gained by 
measurement of high-molecular weight adiponectin compared to 
total adiponectin in PCOS [7] and were supported by other stud-
ies [210]. In contrast, testosterone treatment was associated with 
decreased adipocyte production of high-molecular weight adi-
ponectin and high-molecular weight adiponectin was negatively 
associated with free testosterone levels [225]. These findings sup-
port that the regulation of high-molecular weight adiponectin and 
adiponectin secretion may differ and that both markers could give 
valuable information of inflammatory status in PCOS.  
Ghrelin 
Ghrelin is mainly secreted from the entero-endocrine cells in the 
stomach [226;227]. Ghrelin levels increase during hunger and are 
suppressed during eating. Ghrelin secretion is down regulated 
during conditions of positive energy balance such as obesity 
[227]. Ghrelin is expressed in pancreatic beta-cells and may in-
hibit insulin secretion. Low ghrelin levels were associated with in-
sulin resistance and diabetes [228]. Ghrelin was positively associ-
ated with adiponectin and inversely associated with leptin [3].  
Previous studies reported lower ghrelin levels in PCOS patients 
than in weight matched controls [3;166;229-231] and ghrelin was 
inversely associated with fasting insulin [3]. We and others found 
evidence that central fat mass is the most important predictor of 
ghrelin secretion in PCOS [3;166;232;233]. In our cross sectional 
study, ghrelin showed significant negative correlations with total, 
central, and extremital fat mass in PCOS patients with the highest 
correlation coefficient for central fat mass [3]. No significant asso-
ciations between insulin or HOMA and ghrelin remained after ad-
justing for fat mass, which supported that fat mass is more im-
portant for ghrelin secretion than insulin [3]. In agreement with 
this hypothesis, fasting insulin levels were higher in PCOS vs. 
weight matched controls but ghrelin levels were comparable 
[232]. A hypocaloric diet combined with metformin treatment did 
not change ghrelin levels despite significantly improved insulin 
sensitivity [231].  
The ghrelin receptor is distributed not only in the central nervous 
system but also in ovarian tissue, thus suggesting a possible re-
productive function for ghrelin [234]. Testosterone levels were in-
versely correlated with ghrelin [3;231;233;235;236] and this asso-
ciation remained significant after adjusting for WHR and total fat 
mass [3]. An association between ghrelin and sex hormones was 
further supported by studies reporting significantly increased 
ghrelin levels as testosterone levels decreased during flutamide 
[237] or OCP [236] therapy in PCOS. Changes in ghrelin levels 
were inversely correlated with changes in testosterone and these 
differences remained significant after adjusting for HOMA [237].    
 
Changed ghrelin secretion in PCOS may have important implica-
tions for the energy intake in PCOS. An inverse relationship be-
tween ghrelin and leptin has previously been established in both 
healthy individuals [238] and in PCOS [3;239] and supports that 
the effects of ghrelin on energy homeostasis are opposite the ef-
fects of leptin [238]. Ghrelin levels decrease following food intake 
and the postprandial suppression of ghrelin may be important for 
the feeling of satiety and meal termination [240]. Previous studies 
documented that patients with PCOS had blunted ghrelin sup-
pression following meals [166] and during OGTT [241]. Based on 
these limited data, PCOS patients may have decreased feeling of 
satiety and tend to over-eat during meals. 
In conclusion, ghrelin levels are decreased in PCOS and are in-
versely associated with measures of insulin resistance, fat mass, 
and testosterone. It remains to be established whether changes 
in ghrelin secretion is responsible for possible abnormal appetite 
regulation and obesity in patients with PCOS.     
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Leptin 
Leptin was the first described adipokine and has important effects 
on the regulation of food intake and energy expenditure [242]. 
Leptin is secreted from adipocytes and suppresses food intake 
and promotes energy expenditure [201]. Ob/Ob mice lacking lep-
tin are massively obese, whereas leptin levels are increased in 
obesity and overfeeding, suggesting that obesity may be charac-
terized as a leptin-resistant state [243]. Leptin is expressed in the 
hypothalamus and pituitary and may affect not only the hypotha-
lamic regulation of appetite but also the sympathetic nervous sys-
tem. In mice, leptin injections improved ovarian follicle develop-
ment and leptin receptors were found in ovaries, suggesting that 
leptin may be important for gonadal function [244;245].  
In PCOS, previous studies showed close positive associations be-
tween leptin and BMI, waist circumference, and measures of insu-
lin resistance [3;246-252]. No significant differences were meas-
ured in leptin levels between patients with PCOS and weight 
matched controls despite significant differences in insulin sensi-
tivity [3;247;248;250;253] and leptin levels were unchanged dur-
ing glitazone treatment [201]. Data on the effect of metformin 
treatment on leptin levels were conflicting [201;254], but could 
be due to decreased fat mass during metformin treatment. Most 
studies showed no significant association between leptin and an-
drogen levels [3;247;249] and leptin levels were unchanged dur-
ing anti-androgen treatment in PCOS [253]. These results suggest 
that fat mass is the most important predictor of leptin secretion 
in PCOS. Available data do not support a hypothesis of a potential 
contribution of changed leptin secretion for the pathogenesis of 
PCOS. 
oxLDL and sCD36  
LDL must be oxidized to be taken up by macrophages, therefore 
making oxLDL the atherogenic form of LDL [255;256]. OxLDL lev-
els were increased in PCOS patients compared to weight matched 
controls [8;257]. OxLDL levels were comparable in normal weight 
and overweight PCOS patients, therefore suggesting a minor asso-
ciation between body weight and oxLDL [257]. These findings 
were in agreement with our study reporting a BMI independent 
correlation between oxLDL and glucose and lipid metabolism [8]. 
We and others found a positive association between oxLDL and 
free testosterone, but this correlation became insignificant after 
correcting for BMI [8;257;258]. Increased levels of oxLDL in PCOS 
therefore seem more closely related to insulin resistance than 
with hyperandrogenaemia in PCOS.  
 
CD36 is expressed on the surface of monoytes and macrophages 
[259]. The foam cell formation process is initiated and enhanced 
by the binding of oxLDL to CD36 receptors, making CD36 activity a 
risk factor of cardiovascular disease [259]. Soluble CD36 (sCD36) 
can be measured in plasma and correlated inversely with insulin 
stimulated glucose disposal, whereas a positive association was 
found between sCD36 and insulin and BMI [260]. Patients with 
PCOS had higher sCD36 levels than weight matched controls [8]. 
sCD36 showed a BMI independent significant inverse associations 
with insulin sensitivity and insulin stimulated oxidative glucose 
metabolism, whereas positive correlations were found with FFA 
and lipid oxidation during insulin stimulation [8]. 
During pioglitazone-induced increased insulin sensitivity, sCD36 
levels significantly decreased, whereas no significant changes 
were observed in central fat mass. Multiple regression analyses 
further supported the fat mass independent correlation between 
sCD36 and insulin sensitivity and suggested that sCD36 is an inde-
pendent marker of insulin resistance in PCOS [8]. oxLDL and 
sCD36 showed similar significant associations to measures of fat 
mass and glucose and lipid metabolism and therefore supported 
the hypothesis of a pathogenic relation between CD36 and oxLDL 
[8]. oxLDL decreased during metformin treatment in patients with 
T2D [261], but at present no studies evaluated the effect of met-
formin and/or OCP treatment on sCD36 or oxLDL levels in pa-
tients with PCOS.  
In conclusion, sCD36 could be an important marker of cardiovas-
cular risk in PCOS, but long term studies are needed to test this 
hypothesis and the effects of medical intervention on sCD36 
should be further tested.    
hsCRP and IL-6 
hsCRP is secreted in response to cytokines including IL-6. In-
creased hsCRP was the strongest univariate predictor for the risk 
of cardiovascular events [262]. hsCRP may not only be a marker of 
inflammatory disease but may also amplify the inflammation pro-
cess by further activation of monocytes and endothelial cells 
[262;263]. Patients with PCOS had significantly higher levels of 
hsCRP compared to weight matched controls in several previous 
studies [8;264-269], whereas other studies found no significant 
differences in hsCRP [270;271]. In recent meta-analyses, CPR lev-
els were on average 96% increased in PCOS vs. controls and re-
mained increased after correcting for BMI [272]. We found that 
hsCRP correlated positively with DEXA-scan established fat mass 
measures, whereas no significant correlation was found with tes-
tosterone or measures of glucose metabolism [8]. Pioglitazone-
mediated improved insulin sensitivity was accompanied by de-
creased hsCRP levels, whereas no significant changes were meas-
ured in body composition or testosterone levels, therefore sup-
porting parallel improvements of insulin sensitivity and hsCRP [8].  
Previous studies found no significant differences in IL-6 between 
PCOS patients and controls and no effect of metformin and glita-
zone treatment [8;270;271]. In these studies, hsCRP and IL-6 were 
closely associated and similar positive associations were found 
between IL-6 and hsCRP and body composition [8;265].  
In conclusion, levels of hsCRP were associated with fat mass and 
insulin resistance in PCOS, whereas IL-6 did not seem to contrib-
ute to the pathogenesis of PCOS.  
Prolactin 
Prolactin is secreted not only from the pituitary gland, but also 
from macrophages in the adipose tissue in response to inflamma-
tion and high glucose concentrations [273]. In cross-sectional 
studies, high prolactin was associated with increased white blood 
cell count [274] and autoimmune diseases [275]. The hypothesis 
that prolactin can act as an adipokine was supported by studies in 
patients with prolactinomas. Patients with prolactinomas were in-
sulin resistant and insulin sensitivity increased during treatment 
with dopamine agonist [276-279]. Recently, bromocriptine was 
approved for the therapy of T2D in the United States [280]. 
We recently reported significantly lower prolactin levels in pa-
tients with PCOS vs. controls [4]. Prolactin levels were inversely 
associated with age, smoking status, waist, total cholesterol, TG, 
and LDL and positively associated with HDL in our PCOS popula-
tion. In multiple regression analyses, prolactin was inversely asso-
ciated with LDL after correcting for age, BMI, and smoking status. 
The use of prolactin as a cardiovascular risk marker in PCOS 
should be confirmed in other studies, but were in accordance 
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with recent cross-sectional findings in healthy individuals. In these 
studies, low prolactin levels predicted adverse metabolic out-
comes [281;282] and prolactin significantly increased following 
lifestyle intervention in obese children [283]. 
The findings from previous studies therefore suggested that the 
associations between prolactin and metabolic risk factors could 
be different within and outside the physiological range. In agree-
ment with this hypothesis, in vitro studies found that both low 
and high prolactin levels had adverse effects on beta-cell func-
tion. Prolactin knockout and prolactin receptor deficiency was as-
sociated with reduced beta-cell activity and glucose intolerance 
[284]. In animal studies, prolactin injection was associated with 
weight loss and improved insulin sensitivity [285]. Hypogonadism 
is associated with insulin resistance and obesity [286]. Hyperpro-
lactinemia induces hypogonadism, which is reversed during treat-
ment with dopamine agonists and could increase insulin sensitiv-
ity along with decreased BMI.  
 
We found that prolactin levels were positively associated with es-
tradiol, total testosterone, DHEAS, 17-hydroxyprogesterone, and 
cortisol levels in patients with PCOS [4]. In multiple regression 
analyses, prolactin was positively associated with estradiol, 17-
OHP, and cortisol after correcting for age, BMI, and smoking sta-
tus. In cell and animal studies, prolactin had direct stimulatory ef-
fects on adrenocortical cell proliferation and prolactin stimulation 
promoted increased weight of the adrenal glands [287]. More 
studies are needed to determine the role of prolactin for adrenal 
activity in PCOS. 
 
Conclusion  
Levels of inflammatory markers in patients with PCOS vs. controls 
are summarized in Table 3 along with possible associations be-
tween inflammatory markers and measures of fat mass, insulin, 
and testosterone levels. Future studies are needed to determine 
which of these markers and the cut-offs that should be applied in 
the daily clinic as predictors of for metabolic and cardiovascular 
risk in patients with PCOS.  
 
Table 3: inflammatory markers in PCOS.  
  Associations with  
Inflamma-
tory marker 
Levels in 
PCOS 
BMI/ 
fat 
mass 
Insulin 
sensitiv-
ity 
Testos-
terone 
Adiponectin Decreased (÷) ÷ ÷ ? 
Ghrelin Decreased ÷ ÷ (÷) ÷ 
Prolactin Decreased (÷) (÷) + 
sCD36, ox-
LDL 
Increased + + + none 
CRP Increased + + none 
Leptin Un-
changed 
+ +  (+) none 
IL-6 Un-
changed 
+ none none 
 
÷ ÷ strong inverse association, ÷ inverse association, (÷) weak in-
verse association 
+ + strong positive association, + positive association, (+) weak 
positive association 
None: no association  
 
Other inflammatory and metabolic markers in PCOS 
Recently, a wide range of inflammatory and metabolic risk mark-
ers was measured in PCOS. Some of these markers include the 
chemokines migration inhibitor factor (MIF), monocyte chemoat-
tractant protein (MCP)-1, and macrophage inflammatory protein 
(MIP)-1, the adipokines visfatin and resistin and several others. 
Data on these risk markers have been conflicting and the im-
portance in PCOS remains to be established.   
 
Chemokines 
Chemoattractant proteins, or chemokines, are small proteins that 
activate (chemoattract) leucocytes during the process of inflam-
mation. The mechanism for increased flux of monocytes to the 
adipose tissue with increasing adiposity and the concomitant dif-
ferentiation to macrophages in the adipose tissue may involve ad-
ipose tissue-released chemokines [179;288]. Obesity is positively 
associated with increased levels of the chemokines MIF [289], 
MCP-1 [290], and MIP-1 [291]. Increased MCP-1 levels were re-
ported in PCOS vs. controls matched for weight [292-294] and fat 
mass [292], therefore supporting a hypothesis of increased in-
flammatory activity of the fat tissue in hyperandrogen patients. 
Chemokine secretion was higher in visceral than in subcutaneous 
fat [180], which could explain increased chemokine secretion in 
PCOS [292].  
MCP-1 secretion may be involved in follicular development, ovu-
lation, steroidogenesis, and corpus luteum function, supporting a 
relationship between chemokine secretion and sex hormones 
[295]. In agreement with this hypothesis, we reported a BMI and 
SHBG independent correlation between chemokine levels and 
testosterone in PCOS patients [292]. Testosterone treatment in 
men were associated with increased levels of MIF [296], support-
ing an adverse effect of testosterone on chemokine secretion. 
In obese patients, PPAR-γ agonist treatment reduced chemokine 
levels in vivo [297] and in vitro [180], whereas glitazone, metfor-
min, and OCP treatment failed to improve plasma chemokine lev-
els in PCOS [197;292] despite increased insulin sensitivity [292] 
and decreased testosterone levels [197]. These findings support 
that increased chemokine secretion in PCOS is primarily associ-
ated with fat mass.    
 
Osteoprotegerin 
 High levels of osteoprotegerin predicted cardiovascular events 
[298;299] and heart disease [298;300] in non-PCOS populations. 
These findings suggested that osteoprotegerin could a marker of 
cardiovascular disease. Osteoprotegerin is a soluble decoy recep-
tor for RANKL and was initially discovered as a key regulator in 
bone metabolism [301]. Osteoprotegein is produced in diverse 
tissues including bone, heart, and vascular smooth muscle cells 
[302;303]. Preserved BMD and increased inflammatory state in 
PCOS could be associated with increased osteoprotegerin levels 
[304]. Osteoprotegerin levels were however decreased [305;306] 
or unchanged [304] in PCOS. We found that osteoprotegerin lev-
els were unassociated with measures of insulin resistance and 
pioglitazone treatment significantly decreased inflammatory 
markers, insulin sensitivity, and bone mineral density without af-
fecting osteoprotegerin levels [304]. Based on these results, oste-
oprotegerin is not a good imflammatory and bone metabolic 
marker in PCOS. Osteoprotegerin could however be a marker of 
manifest cardiovascular disease in PCOS, but this hypothesis re-
mains to be confirmed.  
 
Resistin 
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Resistin is an adipokine secreted by macrophages and stromal 
cells in the adipose tissue [201;307]. Resistin may inhibit adipo-
cyte differentiation and is associated with obesity and diabetes. 
Data in patients with PCOS were conflicting as some studies re-
ported no differences in resistin levels between patients with 
PCOS vs. controls, whereas other studies reported increased re-
sistin levels in PCOS [201]. Resistin was positively associated with 
testosterone and increased ovarian androgen production [201]. 
PPAR-γ agonist treatment was associated with decreased resistin 
levels suggesting that resistin may be a marker of insulin re-
sistance in PCOS.  
 
Visfatin 
Visfatin is an adipokine secreted by adipocytes, lymfocytes, and 
several other cell types [201;307]. Visfatin may stimulate the cel-
lular expression of cytokines including TNF-α and IL-6. Visfatin is 
significantly increased in obese individuals and is positively associ-
ated with BMI. Data on visfatin levels after bariatric surgery were 
conflicting as some studies reported decreased levels, but other 
studies reported increased levels of visfatin [201].  
In PCOS, visfatin levels were unchanged or increased and a posi-
tive association between visfatin and measures of insulin re-
sistance was not a consistent finding in previous studies [201]. 
Therefore the importance for visfatin in PCOS remains to be es-
tablished.    
 
Other investigated markers in PCOS were omentin-1 (low levels in 
PCOS), retinol binding protein-4 (increased, normal, or low levels 
in PCOS), and chemerin (increased levels in PCOS). Whether these 
or other markers may add more knowledge on inflammatory sta-
tus in PCOS is undetermined. 
The possible use of HbA1c as a cardiovascular and metabolic risk 
marker is discussed above.   
Treatment principles in PCOS 
Currently the most used treatment modalities in PCOS are OCP 
and/or metformin in combination with life style intervention. 
Some of the effects of OCP and insulin sensitizing treatment on 
hormonal and metabolic outcomes in patients with PCOS have 
been mentioned already in the previous sections.  
OCP  
OCP regulates menstrual cycles and SHBG levels are increased, 
leading to decreased levels of free testosterone and improved hir-
sutism [21;31]. The estrogen component of OCP furthermore sup-
presses LH secretion and thereby the stimulation of ovarian an-
drogen production [195]. OCP are superior to insulin sensitizers 
regarding menstrual regulation and treatment of hirsutism [31]. 
Therefore OCP is often the first-choice in patients with PCOS. Pos-
sible side effects however need to be considered. OCP is associ-
ated with an increased risk of thrombo-embolic episodes [308]. 
Increased risk of thrombo-embolic episodes was associated with 
increased SHBG levels during OCP treatment [308]. Multiple types 
of OCP are available on the market and which types of OCP 
should be preferred in PCOS is debated [30;309]. The estrogen 
fraction of OCP is most often ethinyl estradiol, whereas the pro-
gestin component varies. 2nd generation OCPs have the lowest 
thrombo-embolic risk and is therefore recommended as first 
treatment choice in PCOS. Norgestrel (2nd generation) and levo-
norgestrel (2nd generation) may have more androgenic activity 
than desogestrel (3rd generation), norgestimat (3rd generation), 
and gestodene (3rd generation) [310]. In patients with severe hir-
sutism, OCPs containing a progesterin with antiandrogen activity 
such as cyproterone acetate (Diane Mite) or drospirenone (4th 
generation) therefore could be considered, but limited data are 
available comparing differences in metabolic and clinical out-
comes between different generations of OCP [30;309;310]. 
 
The possible effects of OCP on metabolic risk factors and glucose 
metabolism are currently debated [311]. High testosterone levels 
could redistribute extremital fat to abdominal fat and therefore 
increase the inflammatory activity in PCOS [17]. Body composi-
tion and insulin sensitivity were however unchanged following 
suppression of androgen levels with OCP or ovarian wedge resec-
tion [139;312]. We found that 1 year’s OCP was associated with a 
median weight gain of 1.2 kg, which was evenly distributed on the 
upper and lower body regions [9]. As recently discussed [9], com-
bined treatment with OCP and metformin could be considered in 
normal weight patients with PCOS to avoid weight gain.   
In the general population, OCP was associated with increased in-
sulin levels, but the long term risk of diabetes was not increased 
[308]. Limited data are available in PCOS, but the majority of 
studies reported unchanged insulin sensitivity [311] and inflam-
matory markers [197] during OCP treatment.  
Previous studies supported that OCP may improve LDL, total cho-
lesterol, and HDL, whereas TG levels increased [195]. Previous 
meta-analyses included different types of OCP, which could have 
affected study outcomes. Different generation OCPs could have 
divergent effects on the metabolic risk in PCOS [313]. Six months 
anti-androgen treatment with Diane vs. metformin was associ-
ated with significantly increased adiponectin levels during OCP 
[314]. Unchanged BMI and unchanged insulin sensitivity sup-
ported that increased adiponectin levels could be caused by the 
anti-androgen effect of Diane, but bivariate associations between 
changes in testosterone and changes in adiponectin levels were 
non significant [314]. Thus the improvement of adiponectin could 
be mediated at the receptor level. More studies are needed to 
determine if anti-androgen OCPs are superior to2nd and 3rd gener-
ation OCPs regarding anti-inflammatory effects.  
 
Patient with contraindications such as obesity, previous or family 
history of thrombosis, breast cancer, coagulatory defects, hyper-
tension, or heavily smokers should not be treated with OCP. Al-
ternative treatment modalities are listed in table 4. Hirsutism can 
be treated cosmetically or with local anti-androgen treatment. 
Patients with contraindications for OCP can be treated with spiro-
nolactone [54]. The effect of spironolactone on hirsutism is com-
parable to OCP. Spironolactone is contraindicated in pregnancy 
and must be combined with safe birth control such as an intra-
uterine-device.  
 
Life style intervention and metformin  
Life style intervention and weight loss in PCOS: It is generally ac-
cepted that a more than 5-10% weight loss improves fertility and 
menstrual cycles in women with PCOS [34]. Available data suggest 
that the diet should be restricted to 1500 kcal/day [34]. Improved 
menstrual cycles and decreased testosterone levels were ob-
served when the weight loss was obtained over 2-3 months [34], 
whereas hirsutism was not improved during life style intervention 
[34].  
The optimal diet in PCOS remains to be established. A low glyce-
mic index diet may improve insulin sensitivity by reducing the 
postprandial glucose level and reactive hyperinsulinemia and 
could be of benefit in patients with PCOS [315]. Diets with low 
glycemic index diet often have higher protein content. It has been 
speculated that a high protein diet may cause less hunger and 
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craving for carbohydrates (“carbo-craving”) and compliance may 
therefore increase on a high protein compared to a low protein 
diet [315;316]. In previous studies, the diet composition did not 
affect weight loss [34]. Furthermore, the percentage of weight 
loss seemed to determine the diet effect on hormonal and meta-
bolic outcomes, whereas the type of diet was of minor im-
portance [317;318]. In a recent review, patients on a low glycemic 
index diet tended to have a higher weight loss than patients on 
other diet types [315]. The drop out rate was however higher in 
patients randomized to low glycemic index diets compared to 
other diet types [315]. Diet-intervention studies of longer dura-
tion showed an almost linear weight loss during the first 3 months 
followed by a regression towards baseline values [34]. The high 
drop out rate in previous studies support that patient’s individual 
preferences are important to maintain life style intervention and 
weight loss [34]. In the daily clinic, a comprehensible, healthy diet 
composition seems important for long-term weight loss attain-
ment. 
Gastric bypass and gastric banding are associated with signifi-
cantly improved metabolic risk profile, decreased hirsutism, and 
more regular menstrual cycles [319], but can only be recom-
mended in few selected patients. Recent studies suggested that 
GLP-1 agonists could be applied in PCOS to induce weight loss 
[320], but at present PCOS is not registered as an indication for 
GLP-1 treatment. Especially, pregnancy should be avoided during 
GLP-1 treatment.   
 
Metformin and insulin sensitizers in PCOS: Metformin treatment 
and lifestyle intervention improve insulin resistance and therefore 
insulin stimulation of the adrenals and ovaries decreases. Further-
more, metformin may have beneficial effects on liver, muscle, fat 
tissue, ovary, and inflammatory markers as already described in 
this thesis.  
Weight loss during metformin treatment alone is limited 
[9;35;321]. Metformin combined with life style intervention was 
superior to either treatment alone regarding weight loss 
[171;322;323]. Therefore in the daily clinic metformin could be 
added to life style intervention when life style intervention alone 
does not induce sufficient weight loss. No long term follow up 
studies however evaluated the ability of PCOS patients to achieve 
permanent weight loss on diverse treatment regimes. 
Metformin treatment may slow the progression of diabetes in 
PCOS, but no long term prospective studies exist in PCOS popula-
tions [125]. The indication for medical preventive treatment in 
high risk groups of diabetes has been debated [324]. Insulin sensi-
tizing treatment could be prescribed to postpone diabetes similar 
to preventive treatment for dyslipidemia or hypertension. How-
ever, several studies showed that life style modification in PCOS 
patients had the same positive effects on hormonal and meta-
bolic status than metformin treatment [317;318;322;325;326]. In 
the Diabetes Prevention Study, intensive life style modification 
was more efficient than metformin treatment in decreasing the 
risk of progression to T2D in high risk individuals [327]. Future 
studies need to evaluate the effect of long term treatment with 
insulin sensitizers to postpone diabetes in insulin resistant PCOS 
individuals [324;328]. At present, diet, exercise, and weight loss 
remain the most important treatment modalities in PCOS. 
The use of metformin treatment in normal weight patients with 
PCOS is debated. As already discussed, also normal weight pa-
tients with PCOS may develop T2D [329]. In our study, the effect 
of metformin on body composition was independent of BMI [9]. 
One retrospective, observational study found similar persistence 
rates with metformin and OCP in PCOS, but at 12 months, less 
than 30% patients were still on medical treatment [330]. These 
findings emphasize the difficulty of long term studies in PCOS. In 
our study, only 65/90 patients finished the study [9] and espe-
cially the drop out rate was high in normal weight patients. Treat-
ment in patients with PCOS therefore needs to be individualized 
to ensure adherence to medical treatment. Longer prospective 
studies should determine the indication for treatment in normal 
weight PCOS patients and in patients with only slightly deterio-
rated insulin sensitivity. 
 
Insulin sensitizing treatment is associated with only modest de-
creases in testosterone activity and OCP is more efficient than 
metformin and life style intervention in improving hirsutism and 
acne [35;331-333]. In studies using PPAR-γ agonists as an insulin 
sensitizer, the ovulation rate increased without significant 
changes in testosterone levels [6;136;186;334;335]. The FSH-stim-
ulated estradiol response increased after pioglitazone treatment 
in PCOS patients [335]. Regulation of menses during pioglitazone 
treatment may be caused by increased insulin sensitivity in the 
ovarian granulosa cells and consecutive normalized estradiol se-
cretion. The inability to measure decreased androgen levels de-
spite increased ovulation rate could be due to the applied meth-
ods. Measurements of peripheral serum androgen metabolites 
may be too imprecise to detect minor changes in ovarian hormo-
nal secretion. Measurements of pulsatile testosterone secretion 
and other ovarian secreted hormones may be needed in order to 
characterize discrete improvements of ovarian hormonal secre-
tion. Ovarian catherization was performed in few studies, but this 
procedure can not be carried out in larger clinical studies. PPAR-γ 
agonists are weight neutral. It is possible that the small but signifi-
cant decreases in weight during metformin treatment could ex-
plain the discrepant effects on sex hormones during glitazone and 
metformin treatment.  
A potential limitation of previous studies is the relatively short 
study duration. When PCOS is considered a vicious cycle as de-
scribed in the introduction, hormonal disturbances should im-
prove when the cycle is broken. However, once established dur-
ing puberty, the androgen production by the ovaries may become 
more or less autonomous. Therefore, even if insulin stimulation of 
the ovary is diminished, abnormal hormone production may con-
tinue. Given the limited effects of metformin and life style inter-
vention on hyperandrogenism, OCP is generally first treatment 
choice in patients with hirsutism. 
Some of the treatment principles in PCOS are shown in table 4.  
 
Table 4 treatment principles in PCOS 
Hyperandrogenism 
 OCP 
 Spironolactone  
 (Lifestyle intervention)  
Cosmetic treatment 
Menstrual irregularities 
 Lifestyle intervention 
 OCP 
 Gestagen IUD 
 Metformin 
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The metabolic syndrome 
 Lifestyle intervention 
 Metformin 
Future perspectives 
Hirsutism and PCOS are very common conditions in the daily 
clinic. It is therefore important that general practitioners are fa-
miliar with the diagnosis and treatment of patients with PCOS. En-
docrine diseases are rare in hirsute patients, but should always be 
ruled out. The general practitioner has access to the blood sam-
ples, which are needed to rule out the majority of endocrine dis-
eases in patients with hirsutism and/or irregular menses. Several 
issues, however, remain unclear in PCOS and await further stud-
ies. Close collaboration between general practitioners, endocri-
nologists, and gynaecologists is therefore necessary to ensure op-
timal evaluation and treatment in patients with PCOS.   
 
One main concern in daily praxis is the increased risk of metabolic 
disturbances in patients with PCOS. Insulin resistance is prevalent 
in PCOS and therefore, measurement of fasting metabolic param-
eters should be part of the routine diagnostic evaluation. It is gen-
erally recommended that patients with PCOS are screened for the 
metabolic syndrome, but the optimal use of clinical and biochemi-
cal risk markers remain to be determined. In the present thesis 
several inflammatory markers have been presented in the context 
of PCOS, but the use of these markers in the clinic awaits clarifica-
tion. Furthermore, the presence of obesity and hyperandro-
genemia is associated with insulin resistance [20;336]. When the 
Rotterdam criteria are applied, four different phenotypes of PCOS 
are identified depending on which of the criteria are fulfilled 
[337]. The metabolic and long term risk profile in the four differ-
ent phenotypes may differ. Several studies supported that pa-
tients with anovulation and hyperandrogenism had more severe 
metabolic manifestations than patients with regular menses and 
patients without hirsutism [337]. It is therefore possible that 
screening and follow up should be adjusted to the patients indi-
vidual risk profile. The manifestations of PCOS may change ac-
cording to life style intervention, age, and use of OCP. Weight 
gain could determine ovulatory function in patients with hyper-
androgenism and PCO [101]. It remains to be established how of-
ten individual patients may move from one phenotype to another 
and how this should affect evaluation and follow up.  
 
The symptoms of PCOS most often start in puberty and last 
throughout the reproductive period. The manifestations of PCOS 
are age dependent and age should be considered when the pa-
tient is evaluated. 80% healthy young women had polycystic ova-
ries suggesting that PCO is a normal variant in young women 
[338]. We recently reported that young patients with PCOS were 
characterized by PCO and biochemical hyperandrogenism, 
whereas older patients had more severe hirsutism and more car-
diovascular and metabolic risk factors [79]. At present many pa-
tients request evaluation for PCOS. The consequence of pausing 
OCP for clinical and biochemical evaluation in the individual pa-
tient should however be considered. Given the high prevalence of 
PCO in young individuals, the consequence of performing ultra-
sound should be considered before referral to gynaecological 
evaluation. The majority of young patients with PCOS will benefit 
from treatment with OCP and general advice on life style inter-
vention.  
 
Ethnicity is associated with clinical presentation and metabolic 
risk in PCOS [200]. Inherited variations in 5α-reductase activity 
may explain differences in the prevalence of hirsutism among di-
verse ethnic populations [339]. Several studies documented that 
immigrants in western countries may be at increased risk for life 
style diseases such as obesity and diabetes [340]. Increased risk 
for diseases may be attributable to genetic predisposition or to 
environmental influences such as different exercise or eating hab-
its. We recently reported that North European women with PCOS 
were significantly older and had higher BMI by the time of referral 
compared to women originating from the Middle East [200]. 
North European women with PCOS had increased blood pressure, 
smoked at a higher frequency, and tended to have a more ad-
verse lipid profile than patients originating from the Middle East 
[200]. After correcting for differences in age and BMI, Middle 
Eastern women were characterized by increased androgenicity, 
which could be explained by decreased SHBG, and increased dia-
betes risk [200]. More studies are needed to determine whether 
different ethnic groups with PCOS should be monitored differ-
ently.   
 
The long term risk of PCOS is debated. Recent guidelines recom-
mended yearly follow up of all patients with PCOS with measure-
ments of weight, waist circumference, blood pressure, fasting li-
pids, and screening for T2D [16;341]. In prospective studies, the 
most important predictive factor for the development of T2D was 
obesity [147;342]. Several authors described a high risk for deteri-
orated glucose tolerance during prospective follow-up studies in 
PCOS patients [147;342]. Especially obese PCOS patients have a 
high rate of conversion from normal glucose tolerance to IGT or 
T2D. American PCOS patients had an 8-year incidence of 13.4% 
for T2D in [343] and 16.4% Australian PCOS patients developed 
T2D during 6 years of follow-up [342]. No long term studies exist 
in normal weight PCOS populations. We evaluated clinical and 
metabolic outcomes in 69 hirsute patients with average BMI 25 
kg/m2 after a median observation period of 4 years [329]. During 
follow up, glucose levels had increased and 8.5% patients were di-
agnosed with T2D [329]. The increased glucose levels were seen 
despite unchanged BMI, and the development of IGT and T2D was 
seen in both normal weight and obese individuals. These findings 
suggest that measurement of HbA1c with intervals is reasonable 
also in normal weight patients with PCOS.  
 
Patients with PCOS are considered to be at high risk of developing 
a cardiovascular disease due to the high prevalence of risk factors 
including coronary artery calcification and echocardiographic ab-
normalities [344-346]. At present, however, no long term studies 
exist on well-defined PCOS populations [347]. Retrospective stud-
ies found significantly increased risk of hypertension and CVD in 
women with irregular cycles and the current estimated risk for 
CVD is 4-11 fold increased in PCOS [348-350].The main problem in 
retrospective studies was difficulties in defining PCOS patients 
and finding appropriate control groups. Therefore prospective 
studies on well-defined patient populations are needed to con-
firm this hypothesis. Treatment with statins is rarely indicated in 
reproductive aged women with PCOS. In recent studies, simvas-
tatin decreased androgen levels [181], but was associated with in-
creased insulin resistance [351]. There are insufficient safety data 
on treatment with statins during pregnancy. Therefore, the con-
sequence of measuring yearly lipid status in young patients with 
PCOS is questionable.  
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PCOS patients most often have irregular menses or amenorrhea, 
implying unopposed estradiol exposure of the endometrium. It is 
therefore speculated that PCOS patients carry an increased risk of 
endometrial cancer, but only few epidemiological studies have 
been conducted to confirm this hypothesis [352]. In our study 
population, PCOS was not associated with an increased risk of en-
dometrial cancer [353]. Studies have not been able to document 
higher breast cancer risk in PCOS patients [354].  
 
Several studies showed normal or higher bone mineral density in 
both PCOS and hirsute patients than in control subjects [355-
357]. The positive combination of hyperandrogenemia and possi-
bly high androgen sensitivity may be an explanation for higher 
BMD levels [358]. Furthermore, adiposity is positively associated 
with bone mineral density [359] and recent studies suggested 
that hyperinsulinemia independent of BMI may be protective for 
the development of osteoporosis [360;361]. Increased bone min-
eral density in some previous studies could be associated with de-
creased fracture risk, but limited fracture data exist in patient 
populations with PCOS [362]. Vitamin D levels were lower in pa-
tients with PCOS and hirsutism vs. controls [363-365] and the 
prevalence of vitamin D levels <50 nmol/l in PCOS was 31-85% 
[366]. Vitamin D increases calcium absorption, osteoblast activity, 
and bone formation, whereas vitamin D insufficiency causes de-
fects in bone mineralisation, increases bone turnover, and frac-
ture risk. Vitamin D may be important not only for bone metabo-
lism, but also for the risk of cancer, cardiovascular, and 
autoimmune diseases. Vitamin D levels increased following vita-
min D substitution in patients with PCOS, but insulin sensitivity 
and metabolic risk markers were unchanged [367]. The im-
portance of low vitamin D levels in PCOS and the indication for 
vitamin D treatment therefore needs further evaluation.  
 
Recent studies supported that quality of life is impaired in pa-
tients with PCOS and the risk of depression is approximately eight 
times increased compared to controls [173;368]. The short Form-
36 (SF-36) may be used to reach a health state description and 
can describe the burden of a specific condition [369]. SF-36 scores 
were similar in patients with PCOS and patients with chronic dis-
eases such as diabetes and asthma [173;370]. Cross sectional 
studies reported eight times increased risk for depression in pa-
tients with PCOS [371]. In meta-analyses, especially obesity and 
hirsutism were associated with impaired quality of life in PCOS 
[173;371], whereas menstrual irregularities were less important 
[370]. These results emphasize the possible negative effects of 
PCOS on the patients’ quality of life. OCP did not change depres-
sive symptoms in 36 patients with PCOS despite more regular 
menses and decreased hirsutism [372], but no long term random-
ized studies evaluated the effects of OCP or metformin on quality 
of life. Physical activity and lifestyle intervention may improve 
quality of life, but more studies are needed to determine which 
treatment modalities should be advised in patients with PCOS and 
decreased quality of life. 
We found that 20% reproductive aged patients with PCOS had 
prescriptions of antidepressants during follow up compared to 
15% healthy controls [373]. These data confirmed that a high per-
centage of Danish women use antidepressants. Increased urinary 
excretion of cortisol metabolites in PCOS patients and compensa-
tory hyperactivity of the HPA-axis may be associated with depres-
sion and reduced quality of life [89]. Antidepressants may modu-
late the HPA-axis in PCOS and improve metabolic risk factors 
[374]. Future studies are needed to test this hypothesis. A recent 
Cochrane review found lack of data on the use of antidepressants 
in patients with PCOS and studies on their effectiveness in PCOS 
were requested [375].  
 
Family studies showed a PCOS prevalence of 25-50% in first-de-
gree relatives of PCOS patients suggesting a strong genetic com-
ponent of PCOS [376]. Recent studies used the candidate gene 
approach and investigated genes involved in androgen synthesis, 
secretion, metabolism, and regulation along with genes affecting 
insulin resistance, insulin secretion, and inflammation [376-380]. 
The use of the candidate gene approach in PCOS is limited by the 
fact that the exact pathogenesis for PCOS is unknown. Like other 
common diseases such as T2D, PCOS is most likely a multi-genetic 
disease with several genes having small and additive effects, 
whereas other genes may protect against the syndrome [380]. 
Genetic studies in PCOS are challenged by the diverse definitions 
of PCOS used over time. PCOS is a heterogeneous disease and the 
genetic profile of different phenotypes may differ. Furthermore, 
PCOS can only be diagnosed in reproductive aged women and the 
male phenotype of the syndrome is unknown [376]. Lifestyle and 
environmental factors are of high importance in PCOS, the clinical 
expression may vary considerably over time, and the wide use of 
OCP may minimize the symptoms of PCOS. These challenges of 
genetic studies may explain why initial positive results could not 
be reconfirmed in other study populations. One genome wide as-
sociation study found that three loci were associated with PCOS 
and future large scale and possibly multi-center studies are 
needed to determine the genetic background for PCOS. 
Summary  
Hirsutism affects 5-25% women and the condition is most often 
caused by PCOS. The initial evaluation of hirsute patients should 
include a thorough medical history, clinical evaluation, and stand-
ardized blood samples to diagnose the 5% hirsute patients with 
rare endocrine disorders. The majority of these examinations can 
be performed by the patient’s general practitioner.  
PCOS is a diagnosis of exclusion and is a multiorgan disease af-
fecting most endocrine organs including ovaries, adrenals, pitui-
tary, fat cells, and endocrine pancreas. The manifestations of 
PCOS are diverse and up to 50% patients are normal weight. In 
most cases, however, the severity of symptoms can be related to 
abdominal obesity. Increased inflammation in PCOS can be meas-
ured as decreased adiponectin levels and increased levels of adi-
pokines, chemokines, and interleukins. In the present thesis the 
use of these inflammatory markers is reviewed, but more data in-
cluding hard end points are needed to determine which of these 
markers that should be introduced to the daily clinic.  
Abdominal obesity and insulin resistance stimulates ovarian and 
adrenal androgen production, whereas SHBG levels are de-
creased. Increased testosterone levels may further increase ab-
dominal obesity and inflammation, therefore describing PCOS as a 
vicious cycle. Abdominal obesity and increased activation of the 
inflammatory system is seen in both normal weight and obese 
PCOS patients leading to an increased risk of dyslipidemia, diabe-
tes, and possibly cardiovascular disease. Patients diagnosed with 
PCOS therefore should be screened for elements in the metabolic 
syndrome including weight, waist, blood pressure, HbA1c, and li-
pid status. Our data supported that prolactin and HbA1c levels 
could be markers of cardiovascular risk and should be confirmed 
by prospective studies.   
PCOS is a life-long condition and treatment modalities involve life-
style modification, insulin sensitizers such as metformin, or inhibi-
tion of testosterone levels with OCP. Treatment with pioglitazone 
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supported that increased insulin sensitivity in PCOS is associated 
with improved inflammatory and cardiovascular risk markers. Our 
data supported that one year’s metformin treatment was associ-
ated with a minor but significant weight loss in patients with 
PCOS irrespective of BMI at study inclusion. Treatment with OCP 
improved sex-hormone levels, but was associated with minor 
weight gain. Based on the study results, clinicians should consider 
the combined treatment with metformin and OCP also in normal 
weight patients with PCOS. 
The challenge in the future is to ensure sufficient evaluation and 
treatment of patients with hirsutism and PCOS and to determine 
which subgroups of patients should be treated by their general 
practitioner and which patients should be referred for hospital 
and/or gynecological evaluation and treatment. Furthermore 
more data are needed to determine the optimal follow up pro-
gram regarding metabolic risk in different subgroups of patients 
with PCOS. 
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